United Kingdom

Weight loss drugs have likely proven to be the most challenging medicines to introduce to the National Health Service in England, and lessons should be learned in preparation for other game changing products.

A host of unusually high price increases for UK generics in February led the Department of Health and Social Care to issue the highest number of price concessions seen in almost three years.

IMDRF’s playbook on regulatory reliance was in the spotlight at the Forum’s 29th meeting this week, on the heels of its new midterm regulatory strategy document. 2026 IMDRF chair Singapore used the occasion to announce unprecedented WHO acclaim for the nation’s device regulatory oversight.

Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.

European pricing and reimbursement processes, including in the UK, are on hold for now.

Regulatory uncertainty has affected business planning and funding opportunities for UK medtech companies, says Gerard Hanratty, head of health and life sciences at UK and Ireland law firm Browne Jacobson. On the other hand, the UK industry should not squander the opportunities it uniquely faces.

SamChunDang Pharmaceutical has penned an exclusive licensing and commercialization agreement covering generic versions of oral semaglutide products in the UK and additional European markets.

CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.

Generics Bulletin reviews global regulatory developments across the world.

The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.

SGLT-2 inhibitors should be used to treat patients with type 2 diabetes much earlier in their treatment, the English health technology assessment institute said, adding that using generic dapagliflozin would save the National Health Service £560m.

Revelations about a big underspend on England’s Innovative Medicines Fund for promising new non-oncology medicines have prompted calls for more transparency about how the money is allocated and how the fund is administered.